Actuate Therapeutics (NASDAQ:ACTU) Announces Earnings Results

Actuate Therapeutics (NASDAQ:ACTU) announced its quarterly earnings results on Friday. The company reported ($0.20) EPS for the quarter, FiscalAI reports.

Actuate Therapeutics Price Performance

NASDAQ ACTU traded up $0.03 during midday trading on Friday, hitting $1.01. 109,410 shares of the company traded hands, compared to its average volume of 173,104. The company’s 50-day simple moving average is $1.51 and its 200-day simple moving average is $2.50. The company has a market cap of $24.17 million, a PE ratio of -1.04 and a beta of 0.78. Actuate Therapeutics has a 52 week low of $0.90 and a 52 week high of $9.22.

Institutional Investors Weigh In On Actuate Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Sfmg LLC lifted its holdings in shares of Actuate Therapeutics by 17.6% during the 4th quarter. Sfmg LLC now owns 20,000 shares of the company’s stock worth $122,000 after acquiring an additional 3,000 shares during the period. Barclays PLC increased its holdings in shares of Actuate Therapeutics by 68.6% in the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after purchasing an additional 6,081 shares during the period. State Street Corp boosted its stake in shares of Actuate Therapeutics by 12.8% during the 4th quarter. State Street Corp now owns 56,290 shares of the company’s stock worth $344,000 after acquiring an additional 6,395 shares in the last quarter. ABS Direct Equity Fund LLC bought a new stake in shares of Actuate Therapeutics in the fourth quarter valued at about $40,000. Finally, Wells Fargo & Company MN boosted its position in Actuate Therapeutics by 48.8% in the fourth quarter. Wells Fargo & Company MN now owns 20,146 shares of the company’s stock valued at $123,000 after buying an additional 6,604 shares in the last quarter.

Analyst Ratings Changes

ACTU has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Actuate Therapeutics in a research report on Wednesday, June 10th. Rodman & Renshaw began coverage on shares of Actuate Therapeutics in a report on Thursday, July 30th. They set a “buy” rating and a $6.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Wednesday, June 24th. Finally, Wall Street Zen lowered Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Actuate Therapeutics has an average rating of “Moderate Buy” and an average target price of $13.67.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.